CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
AlgenScribe Therapeutics
Company Type: Therapeutic development
Main focus: Developing a genome-editing platform to improve human health
Company stage: Pre-clinical
Diseases:
Genome-editing tool: CRISPR-Cas9
Funding stage:
Location: Nice, France
Website: www.algenscribe.com
Pipeline:
Partners: Institut Imagine, The Max Delbrück Center
AlgenScribe Therapeutics is a pre-clinical biotechnology company headquartered in Nice, France. The company is developing a genome-editing platform aimed at improving human health by advancing CRISPR-Cas9 technologies to overcome limitations in targeted applications such as off-target effects. AlgenScribe aims to develop a genome-editing platform that could be applied in therapeutic development, as well as bioproduction, diagnostics, and research tools.
